JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

JNJ

189.06

+1.45%↑

ABT

124.63

+0.17%↑

TMO

556.32

-0.37%↓

ISRG

529.81

-1.42%↓

DHR

214.87

+0.44%↑

Search

Beam Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

23.74 -3.57

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

23.71

Max

24.85

Schlüsselkennzahlen

By Trading Economics

Einkommen

7M

-102M

Verkäufe

996K

8.5M

Gewinnspanne

-1,208.257

Angestellte

509

EBITDA

17M

-97M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+70.37% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

4. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

906M

2.8B

Vorheriger Eröffnungskurs

27.31

Vorheriger Schlusskurs

23.74

Nachrichtenstimmung

By Acuity

65%

35%

328 / 373 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Beam Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

30. Okt. 2025, 23:32 UTC

Heiße Aktien

Stocks to Watch: Amazon, Reddit, SPS Commerce

30. Okt. 2025, 23:02 UTC

Ergebnisse

AIA Group 3Q Value of New Business Grew

30. Okt. 2025, 23:45 UTC

Market Talk

Gold Edges Higher Amid Prospects of Continued Central-Bank Demand -- Market Talk

30. Okt. 2025, 23:00 UTC

Ergebnisse

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 3rd Update

30. Okt. 2025, 22:59 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Global Equities Roundup: Market Talk

30. Okt. 2025, 22:59 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Mineral Resources Bear Reckons Lithium Assets May Be Dressed Up For Sale -- Market Talk

30. Okt. 2025, 22:56 UTC

Market Talk

Australia Shares Shaping to Pare Recent Losses -- Market Talk

30. Okt. 2025, 22:35 UTC

Ergebnisse

AIA Group 3Q Value of New Business Margin Was 58.2%, Up 5.7 Ppt on Year >1299.HK

30. Okt. 2025, 22:35 UTC

Ergebnisse

AIA Group 3Q Value of New Business $1.48B Vs. $1.16B>1299.HK

30. Okt. 2025, 22:31 UTC

Ergebnisse

Apple Expects Big December Quarter on iPhone Upgrades -- 2nd Update

30. Okt. 2025, 22:29 UTC

Ergebnisse

Amazon Posts 13% Revenue Jump, Strong Cloud Sales -- 2nd Update

30. Okt. 2025, 22:27 UTC

Ergebnisse

Minas Buenaventura 3Q EPS 66c >BVN

30. Okt. 2025, 22:27 UTC

Ergebnisse

Minas Buenaventura 3Q Rev $431M >BVN

30. Okt. 2025, 22:27 UTC

Ergebnisse

Minas Buenaventura 3Q Net $179M >BVN

30. Okt. 2025, 22:16 UTC

Market Talk
Ergebnisse

Amazon's Grocery Delivery Business Gains Ground -- Market Talk

30. Okt. 2025, 22:14 UTC

Ergebnisse

Review & Preview: A Tech Earnings Storm -- Barrons.com

30. Okt. 2025, 22:00 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

The Day Pharma's Weight-Loss Gold Rush Intensified -- WSJ

30. Okt. 2025, 21:39 UTC

Ergebnisse

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

30. Okt. 2025, 21:26 UTC

Ergebnisse

Amazon Stock Jumps on Earnings Beat. AWS Is Doing Fine. -- Barrons.com

30. Okt. 2025, 21:14 UTC

Market Talk
Ergebnisse

Apple Sees Record Quarterly Services Revenue -- Market Talk

30. Okt. 2025, 21:09 UTC

Market Talk
Ergebnisse

Global Equities Roundup: Market Talk

30. Okt. 2025, 21:09 UTC

Market Talk
Ergebnisse

Amazon Says One-Off Costs Ate Into Operating Income -- Market Talk

30. Okt. 2025, 21:04 UTC

Ergebnisse

Apple Expects Big December Quarter on iPhone Upgrades -- Update

30. Okt. 2025, 21:03 UTC

Ergebnisse

Eldorado Gold 3Q Gold Sales Were 116,529 Ounces at Avg Realized Gold Price Per Ounce Sold of $3,527 >ELD.T

30. Okt. 2025, 21:03 UTC

Ergebnisse

Eldorado Gold 3Q Gold Production Was 115,190 Ounces >ELD.T

30. Okt. 2025, 21:00 UTC

Ergebnisse

Eldorado Gold Skouries on Track for 1Q of 2026

30. Okt. 2025, 21:00 UTC

Ergebnisse

Eldorado Gold 3Q Adj EPS 41c >EGO

30. Okt. 2025, 21:00 UTC

Ergebnisse

Eldorado Gold 3Q Rev $434.7M >EGO

30. Okt. 2025, 21:00 UTC

Ergebnisse

Eldorado Gold 3Q Net $56M >EGO

30. Okt. 2025, 21:00 UTC

Ergebnisse

Eldorado Gold 3Q EPS 27c >EGO

Peer-Vergleich

Kursveränderung

Beam Therapeutics Inc Prognose

Kursziel

By TipRanks

70.37% Vorteil

12-Monats-Prognose

Durchschnitt 42.2 USD  70.37%

Hoch 80 USD

Tief 20 USD

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Beam Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

13 ratings

11

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

16.225 / 20.17Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Very Strong Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

328 / 373 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
help-icon Live chat